Kodiak Sciences Inc. Stock Price, News & Analysis

Kodiak Sciences (Nasdaq: KOD) announced that CEO Victor Perlroth, M.D. will present at two upcoming investor conferences: the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 4:30pm GMT (8:30am PST) and the 8th Annual Evercore Healthcare Conference in Coral Gables on Wednesday, December 3, 2025 at 3:00pm EST (12:00pm PST).

The Jefferies appearance will be a presentation; the Evercore session will be a fireside chat. A live webcast of both events will be available in the Events and Presentations section of Kodiak's investor website at http://ir.kodiak.com/ and will be available for replay for a limited time.

Kodiak (Nasdaq: KOD) reported Week 20 follow-up data from the Phase 1b APEX study of KSI-101 in macular edema secondary to inflammation (MESI) on Nov 5, 2025. Key results: ≥90% of patients in the top two dose levels (5 mg, 10 mg) achieved and sustained absence of intraretinal and subretinal fluid; mean BCVA gains from baseline to Week 20 were +13.4 letters (5 mg) and +15.4 letters (10 mg); proportions with ≥15-letter gain were 62% (5 mg) and 54% (10 mg). Mean OCT CST reductions were up to -230.1 microns. KSI-101 was described as well tolerated and the top two doses are advancing into the actively enrolling Phase 3 PEAK and PINNACLE studies.

Kodiak Sciences (NASDAQ:KOD) has presented new data from their Phase 1b APEX study of KSI-101, a novel bispecific antibody therapy targeting IL-6 and VEGF for treating macular edema secondary to inflammation (MESI). The data shows significant vision improvements, with over 50% of patients in the top two dose levels (5mg and 10mg) achieving ≥15 letter gains.

Key results include mean vision gains of 8.8 to 12.1 letters across dose levels and substantial retinal thickness reductions of 165-240 microns at Week 12. The therapy demonstrated rapid onset, with the majority of patients achieving retinal dryness by Week 8. A separate cohort of diabetic macular edema patients showed 12.0 letter gains at Week 24.

The company is now advancing Phase 3 PEAK and PINNACLE studies testing the 5mg and 10mg doses, with KSI-101 showing a favorable safety profile across all patient groups.

Kodiak Sciences (Nasdaq: KOD) has announced its participation in two major scientific conferences where it will present Phase 1b APEX study data for KSI-101, its bispecific trap-antibody targeting macular edema secondary to inflammation (MESI).

Dr. Charles Wykoff will present the findings at the 25th EURetina Congress in Paris on September 5, 2025, and at The Retina Society 58th Annual Scientific Meeting in Chicago on September 13, 2025. The presentations will focus on KSI-101's dual mechanism of inhibiting both interleukin-6 and vascular endothelial growth factor. Both presentations will be made available on Kodiak's investor relations website.

Harbour BioMed (HKEX: 02142) reported strong 2025 interim results, with total revenue reaching $101.3 million, up 327% year-over-year, and net profit soaring 51-fold to $73.0 million. The company's cash position strengthened to $320 million, a 92% increase from year-end 2024.

Key developments include the BLA acceptance for batoclimab by NMPA for gMG treatment, strategic collaborations with AstraZeneca ($105M equity investment), Windward Bio for HBM9378, and Otsuka for HBM7020. The company advanced multiple clinical-stage programs including porustobart and HBM1020, while expanding its next-generation portfolio with HBM7004 and HBM7020.

The company launched Élancé Therapeutics for obesity treatment and strengthened its platform potential through Nona Biosciences, establishing multiple global partnerships and introducing the AI-assisted Hu-mAtrIx™ drug discovery engine.

Kodiak Sciences (NASDAQ:KOD), a precommercial retina-focused biotech company, will present its glaucoma pipeline programs at the American Chemical Society Fall 2025 Meeting on August 19, 2025, in Washington, D.C.

The company is developing dual-mechanism therapies using its Antibody Biopolymer Conjugate Drug (ABCD) platform. The treatment combines a NLRP3 inhibitor targeting neuroinflammation with an IOP-lowering agent, delivered via quarterly intravitreal injection. Additionally, Kodiak is advancing its VETi™ program, an AI-enabled wearable headset designed to improve clinical trial testing efficiency and accuracy.

Kodiak Sciences (NASDAQ: KOD) reported Q2 2025 financial results and business updates, highlighting progress across its late-stage clinical pipeline. The company's three key assets - tarcocimab, KSI-501, and KSI-101 - are advancing with multiple Phase 3 readouts expected between 1Q 2026 and 1Q 2027.

Notable highlights include promising KSI-101 Phase 1b data in MESI patients, showing rapid anatomical improvements and >90% achieving dryness by week 8. Financially, Kodiak reported a net loss of $54.3 million ($1.03 per share) and ended Q2 with $104.2 million cash, expected to fund operations into 2026. R&D expenses increased to $42.8 million, while G&A expenses decreased to $12.8 million.

Kodiak Sciences (NASDAQ: KOD), a precommercial retina-focused biotechnology company, will host a virtual investor R&D Day on July 16, 2025, from 4:00 PM to 5:30 PM ET. The event will showcase the company's three late-phase clinical assets - tarcocimab, KSI-501, and KSI-101 - with presentations from senior leadership and industry experts.

The company's ABC Platform® uses molecular engineering to combine protein-based and chemistry-based therapies for treating retinal diseases. All three clinical assets are targeting Phase 3 topline data in 2026. The event will be accessible via webcast, with recording available 24 hours after the presentation.

Kodiak Sciences (NASDAQ:KOD) announced its participation in the 2025 Congress of the International Ocular Inflammation Society (IOIS) in Rio de Janeiro, where management and key opinion leaders will present highlights of KSI-101, their investigational treatment for macular edema secondary to inflammation (MESI).

KSI-101 is a first-in-class bispecific intravitreal biologic designed to simultaneously target both interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF). The presentation will address MESI pathophysiology, current treatment limitations, and clinical data for KSI-101. The breakfast symposium is scheduled for June 27, 2025, at 7:00 AM BRT.